As of 2025-03-19, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (92.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 34.37 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -369.8%.
The range of the Relative Valuation is (73.91) - (105.76) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.4x - 36.3x | 28.8x |
| Forward P/E multiples | 19.2x - 30.7x | 25.0x |
| Fair Price | (73.91) - (105.76) | (92.73) |
| Upside | -315.0% - -407.7% | -369.8% |
| Date | P/E |
| 2025-03-14 | -9.97 |
| 2025-03-13 | -9.70 |
| 2025-03-12 | -10.18 |
| 2025-03-11 | -9.65 |
| 2025-03-10 | -9.58 |
| 2025-03-07 | -9.54 |
| 2025-03-06 | -9.44 |
| 2025-03-05 | -9.20 |
| 2025-03-04 | -8.90 |
| 2025-03-03 | -8.75 |
| 2025-02-28 | -9.09 |
| 2025-02-27 | -8.78 |
| 2025-02-26 | -10.26 |
| 2025-02-25 | -10.07 |
| 2025-02-24 | -10.24 |
| 2025-02-21 | -10.68 |
| 2025-02-20 | -10.86 |
| 2025-02-19 | -10.92 |
| 2025-02-18 | -10.77 |
| 2025-02-14 | -10.70 |
| 2025-02-13 | -10.63 |
| 2025-02-12 | -10.20 |
| 2025-02-11 | -9.98 |
| 2025-02-10 | -10.46 |
| 2025-02-07 | -10.83 |
| 2025-02-06 | -11.33 |
| 2025-02-05 | -11.18 |
| 2025-02-04 | -11.24 |
| 2025-02-03 | -11.17 |
| 2025-01-31 | -11.48 |
| 2025-01-30 | -11.73 |
| 2025-01-29 | -11.43 |
| 2025-01-28 | -11.79 |
| 2025-01-27 | -11.96 |
| 2025-01-24 | -12.87 |
| 2025-01-23 | -12.83 |
| 2025-01-22 | -12.80 |
| 2025-01-21 | -12.68 |
| 2025-01-17 | -11.78 |
| 2025-01-16 | -11.69 |
| 2025-01-15 | -12.64 |
| 2025-01-14 | -11.64 |
| 2025-01-13 | -10.80 |
| 2025-01-10 | -11.07 |
| 2025-01-08 | -11.75 |
| 2025-01-07 | -11.87 |
| 2025-01-06 | -11.57 |
| 2025-01-03 | -12.07 |
| 2025-01-02 | -11.86 |
| 2024-12-31 | -11.67 |